Research Article, J Pharm Drug Deliv Res Vol: 6 Issue: 2
In Situ Preparation of Magnetic Fe3 O4 Nanoparticles in Presence of PLGA and PVA as Magnetite Nanocarrier for Targeted Drug Delivery
*Corresponding Author : Tayebeh Shamspur
Department of Chemistry, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran
Received: May 22, 2017 Accepted: July 19, 2017 Published: July 24, 2017
Citation: Ghanbari M, Shamspur T, Fathirad F (2017) In Situ Preparation of Magnetic Fe3O4 Nanoparticles in Presence of PLGA and PVA as Magnetite Nanocarrier for Targeted Drug Delivery. J Pharm Drug Deliv Res 6:2. doi: 10.4172/2325-9604.1000167
Introduction: Drug targeting represents an interesting motivation to prevent side effects and increase doxorubicin cytotoxicity. Magnetic nanoparticles offer new opportunities for developing effective drug delivery systems because they are feasible to produce characterize and specifically tailor their functional properties for drug delivery applications. To improve their stability and biocompatibility, the Fe3O4 nanoparticles are often modified with surfactants or polymers.
Materials and Methods: In the present work, a nanocomposite was synthesized via in situ preparation of Fe3 O4 nanoparticles inside poly lactic glycolic acid and poly vinyl alcohol. The anticancer drug of doxorubicin was loaded on the synthesized nanocomposite in order to targeted drug delivery technique. The nanostructures were characterized by FT-IR, SEM, VSM and XRD techniques. The in vitro drug release from synthesized nanocomposite was investigated as nanocarrier in 2 different pHs (equal blood and tumor environments) at 37° C and extent of drug release was calculated by UV-Vis spectrophotometer.
Results: In vitro drug release experiments showed that the doxorubicin release at pH=6.0 was promisingly more and faster than pH=7.4. The fitted equation of release curves was corresponded to Peppas model.
Conclusion: All these results together suggest that the DOXloaded nanocarrier may serve as a promising magnetic targeting therapy for the treatment of tumor cells.